Skip to main content
OpenTrials
Completed

NCT Number: NCT01151085

Voriconazole (Vfend) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

To collect the efficacy and safety informations of voriconazole related to their appropriate use in daily practice.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Systemic Mycosis Aspergillosis Bacterial Infections and Mycoses Candidiasis Infections Mycoses

Sex eligibility

All sexes

Study type

Observational

About this study

All the subjects whom an investigator prescribes the first voriconazole (VFEND) should be registered consecutively until the number of subjects reaches target number in order to extract subjects enrolled into the investigation at random.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or Female subjects intend to treat their deep mycosis who are prescribed voriconazole (VFEND) by their Physicians.

Exclusion criteria

  • Subject who heve been prescribed voriconazole (VFEND) before.

Treatment and study plan

Voriconazole

Drug

Voriconazole Intravenous Solution 200 mg:

Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.

Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:

administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.

Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.

However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.

In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.

Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily.

Other names: VFEND for Intravenous Use, Voriconazole for Intravenous Use, VFEND Tablets, Voriconazole Tablet

Primary outcomes

  1. Number of Participants With the Frequency of Treatment Related Adverse Events.

    Time frame: 16 weeks

    Adverse events mean all unfavorable events that occur in participants after administration of Voriconazole, irrespective of causal relationship to Voriconazole (including clinically problematic abnormal changes in laboratory test values). Treatment related Adverse Events were evaluated in company with the causal relationship to Voriconazole.

  2. Number of Participants That Responded to Voriconazole Treatment.

    Time frame: 16 weeks

    The primary endpoint was the efficacy ratio (number of effective cases/number of evaluable cases for efficacy assessment) among the cohort comprising the subjects for efficacy analysis.

Secondary outcomes

  1. Number of Unlisted Treatment Related Adverse Events in Japanese Package Insert.

    Time frame: 16 weeks

    Adverse events mean all unfavorable events that occur in participants after administration of Voriconazole, irrespective of causal relationship to Voriconazole (including clinically problematic abnormal changes in laboratory test values). Number of Treatment Related Adverse Events were evaluated in company with the causal relationship to Voriconazole. Unlisted treatment related adverse events were confirmed with listed adverse drug reaction in Japanese package insert.

  2. Risk Factors for the Frequency of Treatment Related Adverse Events -Gender.

    Time frame: 16 weeks

    Number of participants with Treatment Related Adverse Events of Voriconazole to determine whether male or female is significant risk factor.

  3. Risk Factors for the Frequency of Treatment Related Adverse Events -Severity of Infections.

    Time frame: 16 weeks

    Number of participants with Treatment Related Adverse Events of Voriconazole to determine whether severity of infections(mild, moderate or severe) is significant risk factor.

  4. Risk Factors for the Frequency of Treatment Related Adverse Events -Past History.

    Time frame: 16 weeks

    Number of participants with Treatment Related Adverse Events of Voriconazole to determine whether with or without Past History is significant risk factor.

  5. Number of Participants That Responded to Voriconazole Treatment -Severity of Infections.

    Time frame: 16 weeks

    Number of participants that responded to voriconazole to determine whether severity of infections(mild, moderate or severe) is significant risk factor.

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

Vfend Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

Important dates

Study start
2006
Primary completion
2012
Study completion
2012
First posted
Jun 25, 2010
Registry last updated
Aug 8, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.